Trending Now
BeyondSpring (NASDAQ: BYSI) Enter Co-development And Commercialization Agreement With Jiangsu Hengrui...
BeyondSpring (NASDAQ: BYSI) has announced an exclusive co-development and commercialization agreement with Jiangsu Hengrui Pharmaceuticals Co. Ltd in Greater China for BeyondSpring’s experimental drug...
Adagio Therapeutics Inc. (NASDAQ: ADGI) Announces That ADG20 Produced A Neutralizing...
Adagio Therapeutics Inc. (NASDAQ: ADGI) has summarised recent findings that were published in three different publications showing its flagship monoclonal antibody (mAb), ADG20, had...
Covid Stocks Could Represent Huge Value on Sale (NVAX, OTLC, PFE,...
Just when we started to think it was over, Omicron popped up and reminded us that this thing is a whole lot...
Popular News
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Submits sNDA For Approval Of NUPLAZID (pimavanserin)...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has announced the submission of a supplemental new drug application (sNDA) seeking approval from the FDA for its NUPLAZID (pimavanserin)...
MAKE IT MODERN
LATEST REVIEWS
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expects Approval For ORLADEYO In Japan And...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) transitions to a drug launching company to the patients with Hereditary Angioderma. The company expects approval for its ORLADEYO to...
MAKE IT MODERN
PERFORMANCE TRAINING
Preclinical Results for a Novel COVID-19 Vaccine from Soligenix, Inc. Common Stock (NASDAQ:SNGX) are...
There are so many programs seeking a vaccine for COVID-19. The global population and the pharmaceutical industry are so expectant of a timely solution....
Selecta Biosciences Inc. (NASDAQ:SELB) Announces Q3 2020 And Offers Business Updates Including Commencement OF...
Selecta Biosciences Inc. (NASDAQ:SELB) has announced its Q3 2020 financial results and offered its corporate updates.
COMPARE Results Show potential of ImmTOR platform
The company’s...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Reveals Plan To Discontinue Its Vecabrutinib Program
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) recently announced that it will not conduct a Phase 2 clinical trial of its vecabrutinib contrary to previously announced plans.
The...
Wall Street calls for SPY December 31 322 Calls
The market continues to melt higher but mostly in post/pre-market action. For the past two trading sessions, we have seen a gap...
ChromaDex Corp (NASDAQ:CDXC) Publishes Nutritional Protocol Study Results Showing Improved Recovery Time In COVID-19...
ChromaDex Corp (NASDAQ:CDXC) has announced the publication of results of the “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19" study on the medRxiv.org.
COVID-19...
MAKE IT MODERN
[/tdc_zone]